2022 World Conference on Lung Cancer (ePosters)-EP08.01-066. Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?

EP08.01-066. Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?

Back to course

Pdf Summary

A retrospective study was conducted to evaluate the efficacy of immunotherapy (IO) in the treatment of stage IV non-small cell lung cancer (NSCLC) without a driver mutation in real-life clinical practice. The study included patients treated at the Medical Oncology Department of Puerta de Hierro University Hospital between 2016 and 2020. The main outcome measured was overall survival (OS).<br /><br />The study found that IO significantly reduced the risk of death in stage IV NSCLC patients without a driver mutation. The hazard ratio (HR) for death with IO treatment was 0.30, indicating a 70% reduction in the risk of death compared to patients who did not receive IO treatment. The median OS for patients treated with IO was 24 months, compared to 5.7 months for patients without IO treatment.<br /><br />The results of the study suggest that the benefits observed in clinical trials for IO treatment are reproducible in real-life clinical practice. The survival rates at 24 and 36 months were 50.6% and 34.4% respectively for patients treated with IO.<br /><br />Multivariate analysis showed that IO treatment remained a significant predictor of decreased risk of death even after adjusting for other factors such as histology, stage, sex, age, Eastern Cooperative Oncology Group (ECOG) performance status, and Charlson comorbidity index.<br /><br />The study included a total of 380 patients with stage IV NSCLC, of which 59% received IO treatment. The use of IO increased over time, with 43% of patients receiving IO in 2016 and 70% in 2020.<br /><br />In conclusion, this study demonstrates that IO treatment has transferred the increase in overall survival observed in clinical trials to real-life clinical practice for stage IV NSCLC patients without a driver mutation. The findings highlight the importance of accessing new treatments and the reproducibility of clinical trial efficacy in everyday patient care.

Asset Subtitle

Mariano Provencio

Meta Tag

Speaker Mariano Provencio

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

retrospective study

immunotherapy

stage IV non-small cell lung cancer

driver mutation

real-life clinical practice

Medical Oncology Department

Puerta de Hierro University Hospital

overall survival

hazard ratio

multivariate analysis